FibroGen, Inc. Announces Preliminary Clinical Findings on the Positive Effects of FG-4592, Its Investigational HIF-PHI Therapy for Anemia, on Lowering Blood Pressure and Cholesterol in Patients With Chronic Kidney Disease
6/4/2012 10:23:43 AM
SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc., today announced preliminary clinical findings from two ongoing, open-label phase 2 studies demonstrating that FG-4592, its investigational oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (PHI) therapy for anemia, reduced blood pressure in hypertensive patients, reduced cholesterol levels, and improved the ratio of HDL to LDL in lipid profiles, in patients with chronic kidney disease (CKD). Hypertension and dyslipidemia are two of the major risk factors associated with increasing cardiovascular risk in patients with advanced CKD Stages 3b through 5.
comments powered by